C520 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Improving Cash GenerationPositive and improving operating cash flow, together with positive trailing free cash flow, gives Enovis internal funding capacity for operations and investment. If sustained, this cash generation can reduce reliance on external financing and support continued development of its medical technology portfolio.
Revenue Growth And Gross MarginAccelerating reported revenue growth and consistently solid gross margins indicate meaningful demand and underlying product economics across Enovis’s medical device portfolio. Maintaining this combination would provide operating leverage potential and create a stronger foundation for eventual profitability as execution improves.
Robotics Platform ExpansionAdding robotic automation to the ASTRA surgical platform broadens Enovis’s technology offering and strengthens its position in advanced orthopedic procedures. The transaction could deepen surgeon adoption, increase platform relevance, and create longer-term growth opportunities beyond its existing implant and rehabilitation products.
Bears Say
Large And Persistent Net LossesVery large net losses across both the latest trailing period and the prior annual period show that Enovis has not yet established consistent earnings power. Continued losses can limit internally funded growth, weaken returns on capital, and make future performance highly dependent on successful operating improvement.
Elevated Balance-sheet LeverageDebt now stands roughly in line with shareholders’ equity, representing a meaningful increase from earlier periods and reducing financial flexibility. This leverage can constrain capital allocation, increase sensitivity to operating setbacks, and make it harder to fund strategic initiatives while the company remains loss-making.
Robotics Acquisition Margin HeadwindAlthough the robotics transaction expands the surgical platform, management expects it to dilute adjusted EBITDA margin by about 100 basis points in 2027. This creates a near-term integration and profitability burden, requiring successful execution before the expected margin and free-cash-flow benefits emerge.
Enovis News
C520 FAQ
What was Enovis’s price range in the past 12 months?
Currently, no data Available
What is Enovis’s market cap?
Enovis’s market cap is CHF862.37M.
When is Enovis’s upcoming earnings report date?
Enovis’s upcoming earnings report date is Nov 11, 2026 which is in 65 days.
How were Enovis’s earnings last quarter?
Enovis released its earnings results on Aug 06, 2026. The company reported CHF0.728 earnings per share for the quarter, beating the consensus estimate of CHF0.686 by CHF0.043.
Is Enovis overvalued?
According to Wall Street analysts Enovis’s price is currently Undervalued.
Does Enovis pay dividends?
Enovis does not currently pay dividends.
What is Enovis’s EPS estimate?
Enovis’s EPS estimate is 0.63.
How many shares outstanding does Enovis have?
Enovis has 57,669,495 shares outstanding.
What happened to Enovis’s price movement after its last earnings report?
Enovis reported an EPS of CHF0.728 in its last earnings report, beating expectations of CHF0.686. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Enovis?
Currently, no hedge funds are holding shares in CH:C520
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enovis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF31.50 (― Upside)
CHF31.50 (― Upside)
Blogger Sentiment
Bullish
CH:C520 Sentiment 100%
Sector Average 60%
Sector Average 60%
Insider Transactions
Bought Shares
Worth CHF380.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-25.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Enovis
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
C520 Company Deck
C520 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showed solid operational execution and clear commercial momentum—particularly in Recon and extremities—with meaningful innovation catalysts (Arvis, Nebula), margin expansion at the gross level, EPS growth, and improved free cash flow. However, offsetting risks include tariff costs (~$4M), international volatility including Middle East exposure (~$1–2M/month), a Q1 selling-days headwind (~240 bps), a conservative stance on guidance, and an SEC-driven change to adjusted EBITDA presentation that reduces non-GAAP comparability. On balance, positive fundamental performance and a constructive outlook outweigh the near-term headwinds and reporting adjustments.View all CH:C520 earnings summaries